Product image of Lentioo (Drospirenone, Ethinylestradiol) supplied by GNH India

Lentioo

Active Ingredient:
Drospirenone, Ethinylestradiol
Origin:
EU

Lentioo (Drospirenone, Ethinylestradiol)

Drospirenone, the active ingredient in Lentioo, is a combined oral contraceptive presented as an oral tablet for oral use. It is used to prevent pregnancy and to regulate menstrual cycles in women of reproductive age.

GNH India supplies Lentioo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent regulatory standards and offering comprehensive logistics support for global distribution.

Manufacturer / TM Owner

Litcon Pharma Se

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lentioo, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent pregnancy and manage menstrual disorders.

  • Contraception: provides reliable prevention of pregnancy when taken as prescribed.
  • Menstrual cycle regulation: helps achieve more predictable and lighter menstrual bleeding.
  • Acne treatment: may improve mild to moderate acne associated with hormonal fluctuations.

How It Works

  • Drospirenone is a synthetic progestogen with anti‑mineralocorticoid and anti‑androgenic activity, while ethinylestradiol is a synthetic estrogen. Together they suppress the hypothalamic‑pituitary‑ovarian axis, inhibiting luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) release, which prevents ovulation. They also induce cervical‑mucus changes and alter endometrial development, creating an environment unfavorable for fertilization and implantation.

Side Effects

Lentioo may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: tension‑type or migraine‑like pain.
  • Breast tenderness: swelling or discomfort.
  • Weight gain: modest increase in body weight.

Serious or Rare Side Effects

  • Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
  • Hypertensive disorders: severe high blood pressure or stroke.
  • Liver dysfunction: jaundice or abnormal liver enzymes.

Precautions & Warnings

Before prescribing Lentioo, clinicians should consider several safety considerations.

  • Contraindications: avoid in women with a history of thromboembolic events, estrogen‑dependent tumors, or active liver disease.
  • Smoking: do not prescribe to smokers over 35 years due to increased cardiovascular risk.
  • Cardiovascular risk: assess for hypertension, hyperlipidaemia, or diabetes before initiation.
  • Medication adherence: emphasize daily intake at the same time to maintain efficacy.
  • Pregnancy: contraindicated in pregnancy; advise effective contraception.
  • Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Avoid Interactions

Lentioo can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

  • Combined hormonal contraceptives with other estrogen‑containing products: increased risk of thrombosis.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce contraceptive efficacy.
  • Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely)

  • Antiepileptic drugs (e.g., phenytoin, phenobarbital): may lower hormone levels, requiring additional contraception.
  • Antifungal agents (e.g., ketoconazole): may increase hormone concentrations, raising side‑effect risk.
  • St. John’s wort: may decrease contraceptive effectiveness.

Frequently Asked Questions

Lentioo is a combined oral contraceptive indicated for preventing pregnancy and for regulating menstrual cycles in women of reproductive age. It may also be prescribed to improve mild to moderate hormonal acne, depending on clinical judgment.

Drospirenone provides progestogenic activity with anti‑mineralocorticoid and anti‑androgenic effects, while ethinylestradiol supplies estrogenic activity. Together they suppress the hypothalamic‑pituitary‑ovarian axis, preventing the LH and FSH surge needed for ovulation, and they modify cervical mucus and endometrial lining to hinder fertilisation and implantation.

The dosing regimen for Lentioo is determined by the prescribing healthcare professional. Typically, it involves a daily oral tablet taken at the same time each day for a specified cycle, but the exact schedule should follow the prescriber’s instructions.

Lentioo is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it may harm the fetus. It is also not recommended for breastfeeding women, as hormonal exposure could affect milk production and infant health.

To order Lentioo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lentioo contains drospirenone, which offers anti‑mineralocorticoid and anti‑androgenic properties not present in many other estrogen‑progestin combinations. This may result in a lower risk of water retention and can be beneficial for acne, but the overall efficacy in preventing pregnancy is comparable to other approved combined oral contraceptives.

Lentioo tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use after the expiry date printed on the packaging.

Lentioo is taken orally, usually once daily at the same time each day. The tablet is swallowed whole with water and should be taken with or without food, as directed by the prescriber.

Serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis leading to stroke or myocardial infarction, severe hypertension, and liver disorders. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, severe headache, visual changes, or jaundice.

Lentioo should not be used by women with a history of thromboembolic disease, estrogen‑dependent tumors, active liver disease, uncontrolled hypertension, or known hypersensitivity to any component. It is also contraindicated in smokers over 35 years of age and in anyone who is pregnant or breastfeeding.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Drospirenone, Ethinylestradiol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT